Do terpenes get you high? No, terpenes on their own do not produce the characteristic intoxicating high associated with THC. They are aromatic plant compounds found not only in cannabis, but also throughout nature in citrus fruits, pine trees, lavender, hops, rosemary, black pepper and thousands of other plants.
The more interesting answer is that non-intoxicating does not mean biologically inactive. Some terpene and terpenoid molecules interact with receptors, enzymes and signalling systems in the human body. Research is also investigating whether certain terpenes can modify particular effects of THC or other cannabinoids.
That distinction matters. A terpene can potentially influence part of an experience without being the substance that produces cannabis intoxication.
Recent controlled human research provides a good example. D-limonene given without THC did not produce the subjective, cognitive or physiological pattern associated with a cannabis high. When combined with THC at particular experimental doses, however, it reduced some anxiety-related effects of THC while leaving most other THC effects unchanged.
This gives us a much more useful scientific framework than simply saying that terpenes are “psychoactive” or “non-psychoactive”. The better distinction is between intoxication, biological activity and possible modulation of another compound’s effects.
This guide explains whether terpenes can get you high, how they differ from THC, whether cannabis terpenes are psychoactive, whether terpenes can change a THC high, what the entourage effect really means, whether myrcene or limonene can make you higher, and how botanical, cannabis-derived and live resin terpenes fit into the picture.
No. Common terpenes such as limonene, myrcene, alpha-pinene, beta-caryophyllene and terpinolene do not produce the characteristic intoxicating high associated with THC. Some terpenes are biologically active and research suggests certain compounds may influence selected effects of cannabinoids under particular conditions, but this is different from the terpene itself causing cannabis intoxication. A terpene-rich product can still be intoxicating if it also contains THC or another intoxicating cannabinoid, so the complete composition matters.
The phrase getting high is informal, but in cannabis discussions it usually refers to intoxication caused primarily by THC.
Typical features can include changes in:
Not every person experiences THC in exactly the same way, and the intensity depends on dose, route of exposure, tolerance and individual physiology.
The important point is that this recognised cannabis high is principally associated with cannabinoid pharmacology, particularly THC activity at cannabinoid CB1 receptors.
Terpenes are chemically different molecules.
THC and terpenes can occur in the same cannabis flower, but they belong to different chemical categories and perform different roles in the plant.
The main differences between THC and common terpene compounds.
| Characteristic | THC | Common Terpenes |
|---|---|---|
| Chemical category | Phytocannabinoid | Terpenes and terpene-related compounds |
| Main cannabis role | Cannabinoid constituent of glandular resin | Aroma, plant signalling, defence and ecological functions |
| Classic cannabis intoxication | Yes | No |
| CB1 activity | THC is a partial agonist at CB1 | Much weaker, absent or compound-dependent activity according to the terpene and experimental system |
| CB2 activity | THC can interact with CB2 | Some terpene compounds can interact with CB2, with beta-caryophyllene being the best-known example |
| Aroma | Not the main source of characteristic plant aroma | Major contributors to botanical aroma |
| Found outside cannabis | THC is strongly associated with cannabis | Yes, many common terpenes occur throughout the plant kingdom |
THC has a molecular structure that allows it to interact with cannabinoid receptors, particularly CB1 receptors in the central nervous system.
Activation of CB1 signalling alters neurotransmission in brain regions involved in memory, movement, reward, perception and cognition.
This receptor activity is a central part of why THC can produce intoxication.
Route and dose also matter.
The effects of inhaled THC can differ in timing from orally consumed THC because digestion and liver metabolism change how the compound enters circulation and create metabolites with their own pharmacological activity.
Terpenes do not follow the same pharmacological pattern.
The major terpenes commonly found in cannabis do not reproduce the combination of receptor activity, exposure and pharmacology responsible for conventional THC intoxication.
This does not require us to claim that every terpene is incapable of interacting with any cannabinoid receptor.
That older explanation is becoming too simplistic.
Laboratory research increasingly suggests that cannabinoid receptor interactions may occur with certain terpenes under particular experimental conditions.
However, receptor activity observed in a laboratory does not automatically mean a molecule produces cannabis-like intoxication in humans.
Potency, efficacy, concentration, exposure route and pharmacokinetics all matter.
The answer is more nuanced than many older terpene guides suggest.
Previous laboratory research reported little or no relevant cannabinoid receptor activity for several commonly studied cannabis terpenes under the conditions tested.
More recent experimental work has reported low-efficacy CB1 and CB2 receptor activity for certain cannabis-associated terpenes and has investigated whether those compounds can interact with THC signalling.
This does not overturn the central answer to this article.
Low-efficacy receptor activity in an experimental model is very different from a compound producing a meaningful intoxicating cannabis high in a person.
The most scientifically accurate statement is therefore that common terpenes are not established human intoxicants comparable with THC, even though their receptor pharmacology is more complicated than the phrase “terpenes do not interact with CB1” suggests.
This question depends on how the word psychoactive is defined.
If psychoactive is being used casually to mean intoxicating or capable of producing a cannabis high, then common terpene compounds should not be described that way.
If psychoactive is defined much more broadly as any substance capable of influencing the nervous system, mood, perception or behaviour, the terminology becomes less useful.
Some terpenes have demonstrated central nervous system activity in experimental research.
This is why non-intoxicating is generally a more precise description than simply saying every terpene is completely non-psychoactive.
This distinction is central to understanding terpene science.
A molecule can be non-intoxicating while still having biological activity.
Beta-caryophyllene is an excellent example.
It is a common sesquiterpene found in cannabis, black pepper, cloves and other plants.
Research has demonstrated that beta-caryophyllene can activate CB2 cannabinoid receptors.
CB2 activity is not associated with the characteristic intoxicating effects produced through central CB1 activation.
Beta-caryophyllene therefore demonstrates that a molecule can interact with the endocannabinoid system without making somebody high.
Beta-caryophyllene is a C15 sesquiterpene associated with peppery, woody and spicy aromas.
It has attracted particular scientific interest because of its selective activity at CB2 receptors.
This led researchers to describe it as a dietary cannabinoid.
The terminology does not mean beta-caryophyllene is chemically the same type of molecule as THC.
It remains a terpene.
The cannabinoid description refers to its receptor interaction.
Importantly, selective CB2 activation does not create the characteristic psychotropic effect associated with THC acting at CB1.
Possibly, depending on what is meant by feel different.
A powerful aroma can itself influence sensory experience, expectation and perception.
Some terpene molecules also have measurable biological actions in laboratory and animal research.
Controlled human data are much less extensive for most isolated cannabis-associated terpenes.
This means it is reasonable to say that terpenes are biologically interesting.
It is not reasonable to turn every laboratory observation into a guaranteed human effect such as sleepy, focused, euphoric, calm or energised.
This is one of the most interesting areas of current research.
The answer appears to be that some terpenes may modify particular components of the THC experience under certain conditions.
That is different from saying they always make THC stronger.
A controlled human study published in 2024 examined THC and D-limonene.
D-limonene given by itself did not produce pharmacodynamic effects different from placebo under the study conditions.
THC produced the expected acute cannabis effects.
When higher-dose D-limonene was administered with THC, certain anxiety-related ratings were reduced.
Most of the other measured THC effects were not significantly altered.
The study also found that D-limonene did not alter THC pharmacokinetics.
The study is important because it demonstrates why the question should not be reduced to either “terpenes do nothing” or “terpenes make you higher”.
Limonene did not produce its own cannabis-like high.
It also did not simply increase the concentration of THC in the participants’ bodies.
Instead, at the doses studied, it appeared capable of modifying a particular unwanted subjective component of the THC experience.
This is a much more specific form of interaction.
Whether similar effects occur with other terpenes, different doses, oral products or natural cannabis profiles remains an active research question.
There is no strong basis for the general claim that adding more terpenes automatically makes a person higher.
A more complex aromatic profile can certainly make a cannabis product smell or taste different.
Specific terpenes may also influence particular biological responses.
That is not the same as increasing the overall magnitude of THC intoxication.
Claims that terpenes universally make THC stronger, make THC cross the blood brain barrier more effectively or increase cannabinoid bioavailability should therefore be treated cautiously unless demonstrated for the particular compound and formulation being discussed.
There is no established general rule that terpene-rich products make THC intoxication last longer.
The duration of THC effects is strongly influenced by:
A particular terpene could theoretically influence an enzyme, receptor or pharmacodynamic response, but that should not be converted into the blanket claim that terpenes extend a cannabis high.
The entourage effect is a hypothesis that compounds occurring together in cannabis can interact so that the complete mixture produces effects different from an isolated constituent.
Possible interactions can include:
The idea is biologically plausible.
There is also evidence for some specific interactions.
What has not been demonstrated is a universal rule that every full plant profile is automatically more effective, stronger or therapeutically superior because it contains more compounds.
Not as one universal cannabis mechanism.
A comprehensive 2024 review found that current research supports investigation of specific interactions, but the broader hypothesis that terpenes consistently enhance cannabinoid efficacy in an additive or synergistic way remains unproven.
This is an important distinction.
Science can demonstrate one interaction without validating every commercial claim made under the phrase entourage effect.
The limonene and THC study is a useful example of a specific interaction that can be tested directly.
That approach is more rigorous than assuming every terpene modifies every cannabinoid.
This has not been established as a general property of cannabis terpene profiles.
Some terpene and terpenoid molecules have been studied as penetration enhancers or drug-delivery components in pharmaceutical research.
Those experiments can involve concentrations, formulations and routes completely different from ordinary botanical exposure.
They therefore do not prove that adding terpenes to THC or CBD automatically increases cannabinoid absorption in humans.
Claims about bioavailability should be demonstrated for the actual formulation rather than inferred from unrelated experimental systems.
This is another claim that is often repeated too broadly.
Certain terpenoids have been investigated for effects on drug delivery and biological barriers.
However, there is not enough evidence to conclude that ordinary cannabis terpene profiles universally make THC cross the blood brain barrier more effectively in humans.
The controlled human limonene study is particularly relevant because limonene altered some THC-related anxiety ratings without changing measured THC pharmacokinetics.
That finding demonstrates that a terpene-cannabinoid interaction does not necessarily require the terpene to increase THC exposure.
Some can interact with cannabinoid-related biology.
Beta-caryophyllene is the clearest established example because it activates CB2 receptors.
Laboratory research into other cannabis terpenes is continuing, including investigation of weaker CB1 and CB2 receptor interactions and modulation of THC signalling.
Other terpene effects may involve entirely different biological systems.
The endocannabinoid system should therefore not be treated as the only possible target of terpene pharmacology.
No.
Terpenes represent a vast chemical family.
Myrcene, limonene, alpha-pinene and beta-caryophyllene have different structures and physical properties.
They should not be expected to behave identically simply because all four are called terpenes.
This is one reason broad statements such as “terpenes make you relaxed” are scientifically weak.
For a complete breakdown of the major chemical classes, read different types of terpenes.
No, the fact that a terpene came from cannabis does not make the terpene itself equivalent to THC.
Many of the same molecules occur in other plants.
Limonene occurs abundantly in citrus.
Myrcene occurs in hops and lemongrass.
Alpha-pinene occurs in conifers and rosemary.
Beta-caryophyllene occurs in black pepper and cloves.
The molecular source does not turn a non-intoxicating terpene into THC.
Botanical and cannabis-derived versions of the same molecule do not have fundamentally different intoxicating properties simply because they came from different plants.
If molecular identity and stereochemistry are the same, limonene remains limonene.
The difference between botanical-derived terpenes and cannabis-derived terpenes lies primarily in the composition of the complete profile and its botanical origin.
A cannabis-derived product also raises the separate question of whether cannabinoids were carried into the finished material during extraction.
For the complete source comparison, read botanical terpenes vs cannabis-derived terpenes.
No.
Botanical terpenes such as limonene from citrus or pinene from conifer-derived materials do not produce a cannabis-like intoxicating high.
They are concentrated aromatic ingredients rather than THC substitutes.
They can still require careful handling because concentrated terpenes may present irritation, sensitisation or other hazards depending on the specific compound and concentration.
Non-intoxicating should never be interpreted as meaning unlimited exposure is appropriate.
The terpene fraction itself is not expected to produce conventional THC intoxication.
However, this question has an additional complication.
Cannabis-derived aromatic material originates from cannabis, and some extraction or fractionation processes can leave cannabinoid residues in the finished product.
If a product contains THC, any intoxicating effect would need to be assessed in relation to the THC content rather than attributed automatically to its terpenes.
This is why batch-specific cannabinoid analysis can be relevant for cannabis-derived terpene products.
Again, distinguish the terpene fraction from the broader live resin product.
Live resin is normally a cannabis extract derived from fresh-frozen cannabis and can contain substantial cannabinoids.
A refined live resin terpene fraction may be predominantly aromatic compounds, but its cannabinoid content depends on how the fraction was produced.
Therefore:
Read what are live resin terpenes? for the detailed explanation.
A genuinely THC-free terpene product should not produce THC intoxication simply because it contains cannabis-associated aroma compounds.
However, THC-free is a compositional claim that should be supported by appropriate analytical testing where it matters.
This is particularly relevant to cannabis-derived materials because botanical origin alone cannot establish cannabinoid content.
No, not in the conventional cannabis meaning of stoned.
The words high and stoned normally refer to cannabinoid intoxication dominated by THC.
Strong aromas, sensory effects or discomfort from excessive concentrated terpene exposure should not be confused with being stoned.
Concentrated terpenes are potent chemical ingredients.
Depending on the compound, concentration and route of exposure, excessive exposure can cause irritation or other unwanted effects.
Feeling light-headed, uncomfortable, irritated or unwell after exposure to a strong aromatic chemical is not evidence that the compound has produced a THC-like high.
It may instead indicate excessive exposure.
Concentrated terpene ingredients should therefore be handled according to their Safety Data Sheet, supplier instructions and intended application.
Concentrated terpene isolates and blends should not be assumed to be suitable for direct undiluted personal use.
Many are classified as irritants, sensitisers or environmentally hazardous substances in concentrated form.
The correct handling requirements depend on the exact chemical composition.
Always follow the technical documentation for the product rather than treating a concentrated plant-derived ingredient like an ordinary food or fragrance.
Terpenes occur naturally in foods and plants, but concentration changes exposure.
The amount of limonene released while peeling an orange is not equivalent to handling a container of concentrated limonene.
The same principle applies to essential oils and concentrated terpene profiles.
Natural origin tells you where a substance came from.
It does not define its hazard classification at every concentration.
Normal exposure to botanical aromas does not produce THC intoxication.
Humans constantly encounter volatile terpenes through citrus, herbs, flowers, perfumes, food, forests and household products.
Odour perception itself can influence mood, memory and expectation, but this should not be confused with a cannabis high.
Extremely concentrated vapours may also become irritating, which again is a safety issue rather than evidence of THC-like psychoactivity.
Yes, sensory experience can influence subjective state.
Smell is closely connected with areas of the brain involved in memory, emotion and learned associations.
This means an aroma can be experienced as pleasant, energising, familiar or calming without the aromatic molecule being an intoxicant.
The sensory response to lavender, citrus or pine illustrates the difference between experiencing an aroma and becoming intoxicated by it.
Individual terpene compounds are being studied for potential effects on neurological and physiological systems.
However, the evidence varies dramatically between molecules.
Some research is limited to cells or animals.
Some involves complex essential oils rather than isolated compounds.
Human controlled trials are much less common.
It is therefore better to discuss promising research than to state that particular terpene profiles reliably produce a particular mood.
For the wider evidence review, read how do terpenes affect the body and your experience?
No evidence establishes myrcene as an intoxicant comparable with THC.
Myrcene is a common monoterpene found in cannabis, hops, lemongrass, bay and other plants.
It has an earthy, herbal and sometimes musky aroma.
Myrcene is frequently marketed as relaxing or sedating.
Those descriptions are substantially more confident than the available human evidence supports.
Finding myrcene in a cannabis profile does not prove that the compound is responsible for a sleepy or heavy subjective effect.
This is frequently claimed, but robust human evidence is lacking.
Internet explanations often state that myrcene increases blood brain barrier permeability and therefore allows more THC into the brain.
That mechanism has not been established as a reliable explanation of cannabis intoxication in humans.
It is therefore inappropriate to promise that a myrcene-rich profile will make somebody more intoxicated.
This is one of the most persistent cannabis terpene myths.
Mango can contain myrcene.
Its concentration varies according to cultivar, ripeness and other factors.
The presence of myrcene in both mango and cannabis does not demonstrate that eating mango before cannabis reliably increases THC intoxication.
There is currently no strong controlled human evidence supporting that popular claim.
No.
D-limonene is a common citrus-associated monoterpene and one of the most abundant natural terpene ingredients in commercial botanical supply chains.
Controlled human research in which D-limonene was administered alone found no significant pharmacodynamic differences from placebo under the study conditions.
That makes limonene particularly useful when answering this question scientifically.
It can be biologically relevant without acting as an intoxicant.
Potentially, in a specific way.
The controlled human study discussed earlier found that sufficiently high experimental doses of D-limonene reduced certain THC-induced anxiety ratings.
It did not simply intensify the high.
It did not broadly suppress every THC effect either.
This suggests that future cannabinoid-terpene research may reveal selective interactions rather than simple labels such as stronger, weaker, uplifting or relaxing.
No convincing human evidence shows alpha-pinene or beta-pinene producing a conventional intoxicating cannabis high.
Both are common monoterpenes found in conifers, rosemary, herbs and cannabis.
Pinene is frequently associated online with alertness and claims that it counteracts short-term memory effects from THC.
These ideas remain much less firmly established in human clinical research than many terpene charts suggest.
Linalool does not produce a recognised THC-like intoxicating high.
It is an oxygen-containing monoterpenoid associated strongly with lavender and coriander as well as cannabis.
Linalool has been investigated extensively in biological research, but studies involving lavender preparations, isolated linalool, animal models and human aromatherapy should not all be treated as equivalent evidence.
A linalool-rich terpene profile should therefore not be advertised as though sedation or sleep is guaranteed.
No.
Beta-caryophyllene is particularly useful here precisely because it demonstrates that interaction with a cannabinoid receptor does not automatically mean intoxication.
It activates CB2 receptors rather than producing the characteristic central CB1 activation associated with THC intoxication.
This is why beta-caryophyllene can be described as a dietary cannabinoid in scientific literature without being an intoxicating cannabinoid.
There is no established evidence that terpinolene produces THC-like intoxication.
Terpinolene is a C10 monoterpene found in numerous aromatic plants and some cannabis cultivars.
Its aroma can combine fresh, herbal, floral and lightly citrus characteristics.
Claims that terpinolene guarantees one particular mood or cannabis experience remain much stronger than current human evidence.
No conventional cannabis high has been established for humulene itself.
Humulene is a sesquiterpene found prominently in hops and also in cannabis and various aromatic plants.
It is often linked online with appetite suppression and other functional claims.
These should not be presented as predictable human effects without stronger supporting evidence.
Common cannabis-associated terpenes and what can reasonably be said about intoxication.
| Compound | Common Aroma | Produces THC-Like High? | Scientific Context |
|---|---|---|---|
| Myrcene | Earthy, herbal, musky | No established evidence | Biological research exists, but popular sedating and THC-potentiating claims exceed current human evidence |
| Limonene | Citrus | No | Controlled human research found limonene alone similar to placebo and selective modulation of some THC anxiety effects when combined |
| Alpha-pinene | Pine, resinous | No established evidence | Biological activity has been investigated, but human cannabis-effect claims remain limited |
| Beta-pinene | Green, woody, pine-like | No established evidence | Common botanical terpene with developing pharmacological research |
| Beta-caryophyllene | Peppery, woody, spicy | No | Well-characterised CB2 agonist without the characteristic CB1-mediated intoxication of THC |
| Linalool | Floral, lavender-like | No established evidence | Studied in multiple biological contexts, but consumer effect claims require careful interpretation |
| Terpinolene | Fresh, floral, herbal | No established evidence | Aromatic monoterpene with limited controlled human data |
| Humulene | Woody, herbal, hop-like | No established evidence | Sesquiterpene with preclinical research but no established cannabis-like intoxication |
Not reliably by itself.
Terpene analysis provides valuable chemical information, but a cannabis experience depends on much more than a list of aromatic compounds.
Other variables include:
Terpene composition may eventually prove useful for predicting particular aspects of cannabis pharmacology, but current evidence does not justify a simple effects chart that converts limonene into energetic, myrcene into sleepy and pinene into focused.
There are many possible reasons.
The products may contain different minor cannabinoids.
The actual THC dose delivered may differ.
Pharmacokinetics may differ.
Terpenes and other volatile compounds may also contribute to particular subjective dimensions.
Expectation, aroma and sensory experience can influence perception as well.
Terpenes are therefore one plausible part of a much larger explanation rather than the only reason two products differ.
Indica is not a chemical class of terpene.
The traditional indica, sativa and hybrid terminology does not map neatly onto modern cannabis chemistry.
Different plants labelled indica can contain very different terpene and cannabinoid profiles.
The intoxicating component remains determined primarily by the relevant cannabinoids, especially THC, rather than an “indica terpene”.
The same principle applies.
There is no unique sativa terpene responsible for a sativa high.
A cultivar described as sativa may contain limonene, pinene, myrcene, terpinolene, beta-caryophyllene and many other compounds also found across different cannabis categories.
Traditional cultivar labels should not be treated as direct chemical predictions.
Type 1, Type 2 and Type 3 refer primarily to cannabinoid chemotype.
Type 1 is THC-predominant.
Type 2 contains a mixed THC and CBD profile.
Type 3 is CBD-predominant.
The same terpene molecules can occur across all three.
The difference in intoxicating potential therefore comes primarily from cannabinoid composition rather than the terpene being transformed into a different substance.
No.
The terpenes present in CBD-dominant flower are the same broad chemical families found in many other cannabis chemotypes and ordinary plants.
Whether a particular flower or extract has intoxicating potential depends on its cannabinoid composition, not merely on the fact that it has a strong terpene aroma.
CBD and terpenes are both commonly described as non-intoxicating, but they are not the same kind of molecules.
CBD is a phytocannabinoid.
Terpenes are a broad family of plant compounds involved heavily in aroma and plant biology.
CBD has its own receptor and signalling pharmacology and is not simply a terpene without a smell.
Both can occur together naturally in cannabis-derived material.
CBG is another phytocannabinoid.
Like CBD, it belongs to a different chemical family from common volatile terpenes.
CBG should therefore not be confused with aroma compounds such as limonene or myrcene.
The fact that a formulation contains CBG and terpenes does not automatically demonstrate a particular synergy or predetermined consumer effect.
A simplified comparison of three common cannabis-related ingredient categories.
| Feature | Terpenes | CBD / CBG | THC |
|---|---|---|---|
| Primary chemical category | Terpenes and terpenoids | Phytocannabinoids | Phytocannabinoid |
| Major role in aroma | Yes | Limited | Limited |
| Classic cannabis high | No | No conventional THC-like high | Yes |
| Can have biological activity | Yes, compound-dependent | Yes | Yes |
| Occurs widely outside cannabis | Many do | Not generally | Strongly associated with cannabis |
They are major contributors, but the complete answer is more complicated.
Cannabis aroma includes numerous terpene and terpenoid compounds.
Research has also identified other volatile molecules, including esters and sulphur-containing compounds, that can contribute strongly to distinctive cultivar aromas at very low concentrations.
This means the smell of cannabis cannot always be reconstructed perfectly from only the five most abundant terpenes on a laboratory report.
Aroma potency and intoxicating potency are unrelated properties.
The human nose can detect certain volatile molecules at extremely low concentrations.
A substance can therefore smell exceptionally strong without producing intoxication.
Black pepper, lavender, citrus peel and pine resin all demonstrate the same basic principle.
Strong aroma does not mean psychoactive potency.
The same compounds associated with cannabis occur throughout ordinary foods and plants.
Examples include:
The everyday distribution of these compounds is another useful reminder that terpene and THC are not interchangeable terms.
For the complete source guide, read where are terpenes found?
The word drug has several scientific, medical and legal meanings.
Terpenes are chemical compounds, and some have measurable pharmacological activity.
That does not mean every terpene is a controlled drug or medicinal product.
Legal classification depends on the specific substance, product, composition, claims and jurisdiction.
It is therefore better to identify the actual compound and regulatory context rather than treating terpene as one legal category.
Common terpene molecules such as limonene, myrcene, pinene and beta-caryophyllene are not controlled simply because those molecules also occur naturally in cannabis. However, cannabis plant material and a number of cannabinoids, including THC and related controlled compounds, are regulated under UK drugs legislation. A cannabis-derived terpene product therefore needs to be considered according to its actual composition and supply chain rather than relying only on the word terpene.
This distinction is particularly relevant to cannabis-derived terpenes and live resin materials.
An isolated terpene molecule is chemically different from THC.
A cannabis extract may contain both.
Businesses handling cannabis-derived materials should therefore use appropriate analytical data and assess the regulatory status of the actual material involved.
The widely quoted UK 0.2% figure should not be treated as a universal finished-product rule.
It relates to the industrial hemp cultivation framework and eligible low-THC varieties.
It does not mean any cannabis-derived extract becomes lawful merely because THC is below 0.2%.
Finished products and bulk materials need to be assessed under the rules actually applying to their composition and use.
They can.
Terpenes and cannabinoids are separate chemical families, but both can originate within cannabis glandular resin.
Depending on how an aromatic fraction is recovered and refined, cannabinoid material may remain.
The phrase cannabis-derived terpenes therefore does not guarantee either the presence or absence of THC.
Testing provides the answer.
Standard cannabis drug testing does not normally target common terpene molecules such as limonene, myrcene or pinene.
It targets THC or relevant THC metabolites.
The potential issue with a cannabis-derived terpene product is whether THC or another relevant cannabinoid is also present in the complete material.
For the full explanation, read do terpenes show up on a drug test?
A genuinely cannabinoid-free botanical terpene profile should not create THC metabolites simply because it contains compounds also found in cannabis.
For cannabis-derived materials, composition needs to be established rather than assumed.
A product containing THC contamination presents a different situation from purified terpenes alone.
This is why cannabinoid testing can matter even when a product is marketed primarily around its terpene content.
Many terpene compounds are the subject of pharmacological research.
Laboratory, animal and some human studies investigate areas including receptor activity, inflammation, neurological signalling, antimicrobial activity and sensory effects.
That research should not be converted automatically into medical claims for a commercial terpene profile.
A biological mechanism demonstrated in cells or animals does not prove that an ordinary consumer product treats a disease or produces the same outcome in humans.
It is too broad to say that terpenes as a category treat anxiety.
The controlled D-limonene study provides evidence that a specific terpene at particular experimental doses reduced certain anxiety-related effects induced by THC.
That does not establish limonene as a general anxiety treatment or prove that every citrus-forward terpene profile produces the same effect.
Compound, dose, formulation and context matter.
Several terpenes and terpenoids, particularly myrcene and linalool, are frequently associated commercially with sleep and relaxation.
Human evidence supporting simple strain-chart style predictions remains much more limited than the marketing language often suggests.
Aroma preference and relaxation are also subjective.
It is more accurate to describe a profile’s chemical and sensory character than to promise that it will make somebody sleep.
Pinene and limonene are frequently labelled focus or daytime terpenes.
Those descriptions should be understood primarily as commercial or experiential categories rather than proven cognitive outcomes.
There is not currently sufficient evidence to guarantee improved concentration from a terpene profile based only on its dominant terpene.
Some people may associate certain terpene-rich botanical aromas with relaxation or sleepiness.
Preclinical research also investigates sedative-like effects of some compounds.
However, there is no simple rule in which the presence of myrcene or linalool guarantees sedation in humans.
This is especially important when interpreting cannabis labels.
Human responses to strong aromas and concentrated botanical compounds can vary.
Discomfort, sensory overload or irritation can also be interpreted subjectively in different ways.
It would therefore be too strong to say terpenes can never contribute to an unpleasant experience.
At the same time, this is different from the anxiety or paranoia that can occur during THC intoxication.
Not as a general rule.
The limonene human study demonstrates that a terpene can potentially reduce a specific THC-related effect without eliminating the entire THC experience.
This suggests that interaction may be selective.
It does not establish a terpene antidote to THC intoxication.
If somebody is significantly impaired or unwell after THC exposure, attempting to self-treat with terpenes should not replace appropriate medical care.
Potency can mean several things.
If it means the measured amount of THC in a product, adding a terpene does not magically create additional THC.
If it means perceived subjective experience, other ingredients might theoretically influence individual dimensions of that experience.
Those are different concepts.
This distinction is important when people say one strain “feels stronger” even though two samples contain similar measured THC concentrations.
No reliable rule supports that conclusion.
A high terpene concentration can create a very strong aroma.
It can also materially affect formulation characteristics.
It does not follow that doubling terpene content doubles intoxication.
Excessive terpene concentration can instead create safety, irritation, stability or sensory problems.
No.
Aroma intensity and THC concentration are different measurements.
A sample can have a powerful volatile profile without having the highest THC content.
Likewise, a high-THC material can lose aromatic compounds through poor storage while retaining substantial cannabinoid content.
Smell is therefore not a reliable THC potency test.
No evidence supports the idea that adding common terpenes converts CBD into THC or transforms CBD into a conventional intoxicant.
CBD, terpenes and THC remain separate chemical substances.
A formulation can contain several active compounds simultaneously without one chemically becoming another.
No.
Common terpene molecules do not transform into THC merely because they are heated, stored or combined with cannabinoid ingredients.
Terpenes can evaporate, oxidise, isomerise or degrade depending on conditions, but that is completely different from becoming THC.
An individual pure terpene such as limonene does not chemically contain THC inside its molecule.
A commercial terpene mixture may contain multiple ingredients.
A cannabis-derived mixture could also contain trace cannabinoids if extraction and refinement have not fully separated them.
Always distinguish the identity of the terpene molecule from the composition of the complete commercial product.
Selective extraction and subsequent purification can produce aromatic fractions with little or no measurable controlled cannabinoid content.
Whether a particular batch actually meets that description must be established analytically.
The manufacturing route also matters from a regulatory perspective because producing the final fraction may have involved controlled cannabis material earlier in the process.
For the technical side of terpene production, read how are terpenes made and extracted?
Terpenes and cannabinoids can both be produced in cannabis glandular trichomes, but they arise from different branches of plant metabolism and have different chemical structures.
Terpenes are widespread throughout the natural world.
Cannabinoids such as THC, CBD and CBG are much more closely associated with cannabis chemistry.
Terpenes contribute heavily to volatile aroma, whereas cannabinoid pharmacology is much more central to the recognised intoxicating or non-intoxicating cannabinoid effects.
Cannabis did not evolve terpenes specifically to alter the human cannabis experience.
Plants use volatile chemistry in ecological functions including:
Humans subsequently perceive those molecules as aromas and have investigated their biological properties.
Read what do terpenes do? for the broader plant-science explanation.
Cannabis produces many volatile compounds within glandular trichomes concentrated around the flowers.
The same structures also accumulate cannabinoid-rich resin.
This physical proximity partly explains why cannabis terpene discussions and cannabinoid discussions are so closely connected.
It does not mean the molecules are chemically interchangeable.
The volatile profile begins changing after harvest.
Drying, curing, temperature, oxygen and storage can alter the relative concentration of different compounds.
Lighter monoterpenes may be lost more quickly than heavier sesquiterpenes.
This is one reason fresh-frozen live resin terpene profiles can differ from terpene fractions derived from cured material.
Live resin terpene fractions can smell different because fresh-frozen processing aims to preserve volatile compounds that might otherwise decline during drying and curing.
A fresher or more complex aroma does not prove that the terpene fraction itself is more intoxicating.
If a live resin product feels intoxicating, cannabinoid content needs to be considered.
Some individual terpene compounds have been investigated as pharmaceutical penetration enhancers.
That is scientifically interesting, but it needs context.
A drug-delivery study may use a specific isolated terpene at a controlled concentration in a particular formulation.
Those results cannot automatically be applied to every cannabis-derived or botanical terpene profile.
Specific absorption claims require specific evidence.
Laboratory research has investigated interactions between individual terpenes and metabolic enzymes.
The clinical importance of these findings depends on exposure, concentration, route and the specific compound.
It would therefore be inappropriate to say every terpene meaningfully changes medication metabolism at ordinary exposure levels.
People using medicines should not use general terpene information as a substitute for individual medical advice where a clinically significant exposure is being considered.
There is no single safety classification for every terpene in every application.
Safety depends on:
Many terpenes have long histories of use in foods, fragrances and botanical products.
Concentrated terpene ingredients can nevertheless be irritating or sensitising and must be handled according to their actual hazard documentation.
Some terpene compounds and particularly their oxidation products can contribute to skin sensitisation in susceptible individuals.
Exposure to oxygen during prolonged storage can therefore matter not only to aroma quality but also to chemical composition.
This is one reason fresh, properly stored material and suitable packaging are important.
Terpenes can change chemically during storage.
They can evaporate, oxidise and form degradation products.
The rate depends on the profile, temperature, oxygen exposure, light and packaging.
There is no universal expiry period applying to every terpene mixture.
The manufacturer’s stated shelf life or retest period should be followed for the specific ingredient.
No evidence suggests that simply heating ordinary terpene molecules turns them into THC-like intoxicants.
Heat can change terpenes in other ways.
It can increase evaporation and, under suitable conditions, contribute to oxidation, isomerisation or thermal degradation.
Those reactions relate to chemical stability and safety rather than creating a cannabis high.
For the full temperature guide, read terpene evaporation, burning and degradation temperatures.
Yes.
Individual pure terpene compounds have characteristic physical properties including vapour pressure and normal boiling point.
They also evaporate below their boiling point.
Boiling point therefore should not be interpreted as the exact temperature at which a terpene suddenly becomes active, inactive, safe, unsafe or intoxicating.
There is an important difference between intoxication in the THC sense and adverse effects from chemical overexposure.
Concentrated volatile chemicals can cause unpleasant or harmful effects when exposure is excessive.
That does not mean they are producing the characteristic cannabinoid intoxication commonly described as getting high.
Trying to use excessive terpene exposure to produce an altered state would be unsafe and should not be confused with normal botanical use.
The phrase “terped out” is informal industry or consumer slang rather than a medical diagnosis.
It is sometimes used to describe light-headedness, discomfort, headache or sensory overload associated with excessive terpene exposure.
Those sensations should not be taken as evidence that terpenes produce the same pharmacological intoxication as THC.
If concentrated exposure makes someone feel unwell, the sensible response is to stop exposure and follow appropriate safety guidance.
There is no established evidence that ordinary terpene exposure reliably produces the characteristic euphoria associated with intoxicating cannabinoids.
Positive mood responses to an aroma can certainly occur.
That is different from a reproducible pharmacological cannabis high.
The words pleasant, uplifting and euphoric should therefore not be treated as interchangeable scientific outcomes.
Common terpene profiles are not recognised as producing the characteristic impairment associated with THC.
However, exposure to excessive concentrations of any potent volatile chemical can make someone feel unwell or uncomfortable.
A product’s safety should therefore be assessed according to its actual composition rather than assuming that non-intoxicating means incapable of causing any adverse effect.
Terpenes themselves are not equivalent to THC intoxication.
However, the complete product matters.
A cannabis-derived product containing intoxicating cannabinoids can impair driving even if its marketing emphasises terpenes.
People should therefore assess the full ingredient and cannabinoid composition rather than assuming that the word terpene guarantees a non-intoxicating finished product.
No.
THC content cannot be established reliably from aroma.
A THC-free botanical profile can smell strongly cannabis-like.
A cannabis-derived aromatic fraction can also contain very little THC.
Conversely, a cannabinoid-containing extract may have lost much of its aroma through processing or poor storage.
Chemical analysis is the appropriate way to determine cannabinoid content.
Yes.
This is the principle behind strain-inspired botanical terpene profiles.
Individual molecules found in cannabis can be obtained from other plant sources and recombined in ratios designed to reproduce aspects of a cultivar’s aroma.
The resulting profile can smell recognisably cannabis-inspired without containing THC simply because of that aroma.
This is explored in detail in botanical terpenes vs cannabis-derived terpenes.
Smell and intoxication are separate chemical properties.
Modern cannabis aroma research also shows that some characteristic pungent or skunky notes arise from potent volatile compounds outside the conventional terpene family.
These molecules can have extremely low odour thresholds.
A tiny concentration can therefore produce a powerful smell without representing a meaningful intoxicating dose of THC.
Yes.
The plant kingdom contains thousands of terpene-producing species that do not produce a cannabis cannabinoid profile.
Commercial botanical terpene ingredients can therefore be manufactured completely independently from cannabis.
Even cannabis-derived aromatic material can potentially be refined so that cannabinoids are absent or below relevant analytical limits, although this must be demonstrated for the specific batch.
Yes.
Highly purified cannabinoid isolates and refined distillates can contain very little of the original plant’s volatile terpene profile.
Terpenes and cannabinoids can therefore be separated technologically even though they may occur together in the original plant.
No.
Total terpene percentage measures aromatic chemistry, not THC intoxication potential.
A product with 4% terpenes is not automatically twice as intoxicating as one with 2% terpenes.
Likewise, a particularly aromatic cannabis flower is not automatically stronger in THC.
No single dominant terpene currently provides a reliable intoxication score.
A myrcene-dominant profile may occur in one cultivar and a limonene-dominant profile in another, but THC dose and broader chemistry remain critical.
The dominant terpene is useful for understanding aroma and chemical composition.
It should not be used as a substitute for cannabinoid data.
Potentially.
Minor compounds can have powerful aromas because human odour thresholds vary greatly.
Some may also possess biological activity.
Whether a trace compound materially changes human cannabinoid pharmacology at the concentrations present is a separate question that needs experimental evidence.
This distinction between sensory significance and pharmacological significance is often overlooked.
Whether choosing botanical or cannabis-derived terpene products, useful information includes:
Terms such as premium, pure, natural, live or laboratory grade do not replace analytical documentation.
A terpene analysis identifies or quantifies aromatic compounds.
A cannabinoid analysis addresses a different question.
If the concern is whether a cannabis-derived aromatic product contains THC, cannabinoid testing is the relevant analytical evidence.
A terpene chromatogram alone does not necessarily prove that cannabinoids are absent.
Gas chromatography is particularly well suited to volatile compounds such as terpenes.
GC-MS can help identify individual compounds by combining chromatographic separation with mass spectrometry.
GC-FID is also widely used for quantitative terpene analysis.
Cannabinoids are often analysed separately using techniques selected for cannabinoid chemistry.
Different molecular structures can have different biological properties.
Monoterpenes such as limonene, myrcene and pinene are chemically different from sesquiterpenes such as beta-caryophyllene and humulene.
Oxygenated terpenoids such as linalool add another layer of chemical diversity.
It is therefore scientifically reasonable to study them individually rather than assuming one result applies to the entire terpene family.
For consumer products, aroma and chemical composition are usually more defensible selection criteria than guaranteed effect labels.
A citrus-forward profile can reasonably be described as citrus-forward.
A beta-caryophyllene-rich profile can be accurately described chemically.
Calling one “euphoria”, another “sleep” and another “focus” implies a level of predictable human pharmacology that is not currently supported for most terpene profiles.
Better is subjective.
Terpenes clearly contribute significantly to aroma and sensory identity.
They may also contribute to specific biological interactions.
Whether a terpene-rich cannabis product is therapeutically or subjectively better than another formulation depends on the complete chemical composition and the outcome being measured.
It should not be assumed merely from terpene concentration.
Terpenes are major contributors to plant aroma and are biologically active molecules. They do not produce the characteristic THC-like cannabis high on their own. Some terpenes can interact with cannabinoid or other biological receptors, and controlled human evidence now shows that at least one terpene, D-limonene, can modify a specific THC-induced effect without itself producing THC-like intoxication. The much broader claim that terpene profiles universally make THC stronger, improve cannabinoid bioavailability or create predictable effects remains unproven.
Current evidence does not justify claiming that:
These remain much more conditional than popular cannabis terpene charts often suggest.
No conventional THC-like cannabis intoxication should be expected from common purified terpene compounds simply because THC is absent.
This is one of the most useful practical answers to the question.
If an allegedly THC-free terpene product produces a strong cannabis-like intoxicating effect, the actual composition of the product deserves scrutiny.
Yes.
A commercial product can contain ingredients other than THC and terpenes.
Some cannabinoids and synthetic cannabinoid-like substances can have intoxicating properties.
Therefore, if assessing whether a particular finished product can get someone high, the entire ingredient and analytical profile matters rather than just whether terpenes are listed.
No.
Synthetic cannabinoids are a completely different group of compounds designed to interact with cannabinoid receptors, often with potent effects.
They should not be confused with naturally occurring terpene ingredients.
The shared word cannabis in marketing or discussion does not make these chemical categories equivalent.
The question sits at the intersection of three things that are frequently confused:
Terpenes are unquestionably important to aroma.
Some also have pharmacological activity.
Neither fact means they automatically produce cannabis intoxication.
Keeping these concepts separate makes the entire subject easier to understand.
No. Common terpene compounds do not produce the characteristic intoxicating cannabis high associated with THC. Some terpenes are biologically active and may influence particular cannabinoid effects under specific conditions, but that is different from producing intoxication themselves.
Terpenes are not established as producing a conventional THC-like high. Strong aromas or excessive concentrated exposure can create sensory or unwanted physical effects, but these should not be confused with cannabis intoxication.
The term psychoactive can be defined very broadly. Some terpenes have biological activity involving the nervous system, but common terpenes are not intoxicating in the same way as THC. Non-intoxicating is therefore usually the more precise term.
Research is evolving. Some earlier studies found little relevant cannabinoid-receptor activity for common terpenes, while newer laboratory research has reported low-efficacy CB1 and CB2 activity for certain compounds. This does not establish that terpenes produce THC-like intoxication in humans.
THC produces its characteristic intoxicating effects largely through cannabinoid CB1 receptor activity in the central nervous system. Common terpene compounds do not reproduce the same pharmacological pattern, potency and exposure responsible for conventional THC intoxication.
There is no universal evidence that terpenes simply make THC stronger. Specific interactions can occur. Human research has shown that D-limonene can reduce certain THC-induced anxiety effects at particular doses without broadly increasing THC effects or changing THC pharmacokinetics.
Possibly. Emerging evidence suggests individual terpenes may influence particular components of the THC experience. That is different from saying every terpene increases, decreases or predictably controls the entire high.
This has not been established as a general effect. Some terpenes have been studied in pharmaceutical drug-delivery systems, but those findings do not prove that normal cannabis terpene profiles automatically increase THC absorption in humans.
This claim is often overstated. Certain terpenoids have been investigated in drug-delivery research, but there is not sufficient evidence to state that ordinary terpene profiles universally increase THC transport across the blood brain barrier in humans.
No established evidence shows myrcene producing a THC-like intoxicating high. It is an aromatic monoterpene found in cannabis, hops, lemongrass and other plants.
The claim that myrcene reliably increases THC intoxication or helps THC enter the brain more efficiently has not been established in controlled human research.
There is no strong controlled human evidence that eating mango reliably increases cannabis intoxication. Mango can contain myrcene, but concentration varies and the shared presence of one terpene does not demonstrate a meaningful THC-potentiating effect.
No. In a controlled human study, D-limonene administered by itself did not produce pharmacodynamic outcomes significantly different from placebo under the conditions tested.
Yes, specific interaction has been demonstrated in controlled human research. Higher experimental doses of D-limonene reduced certain THC-induced anxiety ratings while leaving most other THC effects and THC pharmacokinetics unchanged.
No established human evidence shows alpha-pinene or beta-pinene producing conventional cannabis intoxication. Both are common plant terpenes found in conifers, herbs and cannabis.
Linalool is not established as a THC-like intoxicant. It is an aromatic monoterpenoid found in lavender, coriander and cannabis and has been studied in numerous biological contexts.
No. Beta-caryophyllene is a selective CB2 receptor agonist, but CB2 activation does not produce the characteristic CB1-mediated intoxication associated with THC.
No. A terpene does not become intoxicating simply because it was extracted from cannabis. However, a cannabis-derived commercial product may also contain cannabinoids, so its complete composition should be considered.
No. Botanical terpene ingredients such as limonene and pinene do not produce conventional THC intoxication. Concentrated terpene ingredients can still require careful handling because non-intoxicating does not mean free from chemical hazards.
They can, depending on how the aromatic fraction was extracted and refined. Terpenes themselves are not THC, but cannabinoid carryover can occur in cannabis-derived materials. Testing is needed to determine the composition of a specific batch.
The terpene fraction itself is not the source of conventional cannabis intoxication. However, live resin products can contain substantial cannabinoids, including THC, and some terpene-rich live resin fractions can retain cannabinoids depending on processing.
A genuinely THC-free terpene product should not produce a conventional THC high simply because it contains cannabis-associated aromatic molecules.
No. Stoned normally describes cannabinoid intoxication, particularly from THC. Terpene aromas or unwanted effects from excessive exposure should not be confused with that pharmacological state.
Excessive exposure to concentrated volatile compounds can cause unwanted symptoms in some circumstances. Light-headedness or discomfort should be treated as possible overexposure rather than evidence of a THC-like high.
Normal exposure to plant aromas does not produce conventional cannabis intoxication. Smell can influence sensory experience and emotion, but this is different from becoming high from THC.
Individual terpene compounds are being investigated for nervous-system and behavioural effects, but evidence varies considerably. Aroma itself can also influence subjective experience. It is too broad to say every terpene profile produces a predictable mood effect.
Myrcene and linalool are commonly marketed as relaxing or sleep-related terpenes, but controlled human evidence does not support treating the presence of either compound as a guarantee of sedation.
Pinene and limonene are frequently marketed for focus or daytime use, but there is not strong enough human evidence to guarantee improved concentration from a terpene profile based solely on its dominant compound.
Standard cannabis drug tests do not normally target common terpene molecules. They target THC or relevant THC metabolites. Cannabis-derived terpene products should be assessed for cannabinoid carryover where this matters.
A genuine botanical terpene profile made without cannabis cannabinoids does not produce THC metabolites merely because some of the same aroma molecules also occur in cannabis.
Common terpene molecules are not controlled simply because they also occur naturally in cannabis. Cannabis plant material and certain cannabinoids are controlled, so cannabis-derived commercial materials need to be assessed according to their actual composition and supply chain.
The 0.2% figure relates to the UK industrial hemp cultivation framework and is not a universal finished-product limit for cannabis-derived terpene or extract products.
Natural origin does not guarantee safety at every concentration. Concentrated terpenes can be irritating or sensitising and should be handled according to their technical documentation, Safety Data Sheet and intended application.
Concentrated terpene ingredients should not automatically be regarded as suitable for direct undiluted personal use. The appropriate handling and formulation requirements depend on the exact composition and intended application.
No. Heating can cause terpene evaporation, oxidation, isomerisation or degradation, but ordinary terpenes do not simply convert into THC through heat.
No. Terpene percentage measures aromatic composition, not THC intoxication. A stronger aroma or higher terpene concentration does not automatically mean a product will be more intoxicating.
No. Aroma intensity and cannabinoid potency are separate properties. Strong-smelling material is not automatically high in THC, and high-THC material can lose aroma through poor storage.
Specific terpene-cannabinoid interactions are being investigated, but the broad claim that every terpene profile creates a clinically meaningful entourage effect remains unproven. Effects need to be demonstrated for specific compounds, concentrations and outcomes.
No, terpenes do not produce the characteristic intoxicating high associated with THC.
That simple answer is correct, but the science behind it is considerably more interesting than the old idea that terpenes are merely inactive scent molecules.
Terpenes are biologically active compounds.
Some interact with receptors, enzymes and signalling pathways. Beta-caryophyllene has well-characterised CB2 receptor activity. More recent laboratory research is also exploring weak CB1 and CB2 activity among other cannabis-associated terpenes.
None of this means common terpene profiles behave like THC in humans.
Controlled human evidence supports that distinction. D-limonene administered alone did not produce a THC-like pharmacodynamic response. When administered alongside THC at particular experimental doses, however, it selectively reduced some anxiety-related effects without broadly increasing intoxication or changing THC pharmacokinetics.
That gives us a useful way to think about terpenes.
They are not the engine of cannabis intoxication, but individual compounds may influence parts of the wider chemical and sensory experience under certain conditions.
The evidence needs to be considered compound by compound rather than converted into simplistic effects charts.
Myrcene has not been proven to make everyone sleepy or to make THC cross the blood brain barrier more efficiently. Pinene is not a guaranteed focus molecule. Limonene does not automatically make a person energetic. A high terpene percentage does not mean a stronger high.
The source also does not change this fundamental principle.
A botanical limonene molecule does not become non-intoxicating while cannabis-derived limonene becomes intoxicating. The individual molecule can be chemically the same. What changes is the complete mixture around it.
Cannabis-derived and live resin terpene products require an additional distinction because the commercial material can contain cannabinoids if extraction and refinement have not fully separated them. If such a product contains THC, the THC may be intoxicating. That does not mean the terpene itself produced the high.
The best scientific answer to the question “do terpenes get you high?” is therefore:
Terpenes are non-intoxicating aromatic plant compounds rather than THC substitutes. They can have biological activity, and some may modify specific aspects of cannabinoid pharmacology, but they do not independently reproduce the conventional THC cannabis high.
Continue through the Canavape terpene knowledge hub with how terpenes affect the body and your experience, different types of terpenes, whether terpenes show up on a drug test, botanical terpenes vs cannabis-derived terpenes, what live resin terpenes are, where terpenes are found, how terpenes are made and extracted and terpene evaporation and degradation temperatures.
You can also explore the complete Canavape terpene collection and our specialist cannabis-derived terpene profiles.
This article is provided for educational purposes and discusses terpene chemistry, cannabis pharmacology and current scientific evidence. It does not provide medical or legal advice. Concentrated terpene ingredients should be handled according to their technical and safety documentation, and cannabis-derived materials should be appropriately assessed for cannabinoid content and regulatory status.
Message us directly
I will be back soon
